TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00388076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: pazopanib in combination with paclitaxel in Part 1, paclitaxel and carboplatin in Part 2, and paclitaxel and lapatinib in Part 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: pazopanib in combination with paclitaxel in Part 1, paclitaxel and carboplatin in Part 2, and paclitaxel and lapatinib in Part 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: pazopanib in combination with paclitaxel in Part 1, paclitaxel and carboplatin in Part 2, and paclitaxel and lapatinib in Part 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Lapatinib in combination with pazopanib and paclitaxel in Part 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: in combination with pazopanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: in combination with pazopanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: in combination with pazopanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: in combination with pazopanib
Study: NCT01248689

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: concentration profile 1
Description: IOP will be measured under this order of sevoflurane concentrations:~7%, 5%, 2%, 0.5%

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: concentration profile 2
Description: IOP will be measured under this order of sevoflurane concentrations:~7%, 2%, 5%, 0.5%

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: concentration profile 3
Description: IOP will be measured under this order of sevoflurane concentrations:~7%, 0.5%, 5%, 2%
Study: NCT00987389

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma Exchange
Description: Plasma exchange is a procedure whereby blood is taken from the body and separated by a machine into blood cells and plasma, which is the liquid part of blood. The plasma is discarded and the blood cells are returned to the body with a plasma substitute.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma Exchange
Description: Plasma exchange is a procedure whereby blood is taken from the body and separated by a machine into blood cells and plasma, which is the liquid part of blood. The plasma is discarded and the blood cells are returned to the body with a plasma substitute.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Plasma Exchange
Description: No plasma exchange.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Plasma Exchange
Description: No plasma exchange.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids [Standard Dose]
Description: During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following a standard regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids [Standard Dose]
Description: During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following a standard regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids [Reduced Dose]
Description: During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following a reduced regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids [Reduced Dose]
Description: During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following a reduced regimen.
Study: NCT02521935

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Complete traditional dentures
Description: Arm 1-Standard Treatment Sequence for Traditional Removable Dentures in a Dental School Clinic (9 Appointments):~Appointment 1: Examination \& diagnosis \& initial impressions.~Appointment 2: Secondary impressions.~Appointment 3: Secondary or definitive impressions (Often 2 appointments are needed to border mold and impression)~Appointment 4: Maxillo-mandibular jaw relation records (both centric and vertical relation). Tooth selection.~Appointment 5: Wax-trial denture try-in.~Appointment 6: Insertion and instructions for care of definitive prostheses.~Appointments 7-9 Post adjustments

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Complete CADCAM dentures
Description: Arm 2-Standard Treatment Sequence for Digital Dentures in a Dental School Clinic (5 appointments):~Appointment 1: Exam, diagnosis, \& tray selection (begin impressions)~Appointment 2: Definitive impressions and Maxillomandibula relations~Appointment 3: Wax-trial arrangement~Appointment 4: Insertion and instructions for care of definitive prosthesis~Appointment 5: Post adjustment/s (Less post insertion adjustments are anticipated due to CADCAM milling of the denture base and less polymerization shrinkage
Study: NCT02908282

Intervention type: DEVICE
Group type: OTHER
Intervention: REMOGEN OMEGA
Description: Lubricant eye drops: preservative-free, hypotonic microemulsion of polyunsaturated fatty acids and hydrating polymers provided in single-dose containers of 0.25 ml.

Intervention type: DEVICE
Group type: OTHER
Intervention: Povidone
Description: Artificial tears: preservative-free eye drops containing 2% povidone.
Study: NCT03979781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tailored antiplatelet selection
Description: antiplatelet selection guided by platelet function phenotype and/or key pharmacogene genotypes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: antiplatelet selection using standard of care
Study: NCT03524989

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: 40 daily sessions, 60 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 2 months.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM treatment
Description: 40 daily sessions, 60 minutes of 21% oxygen at pressure of 1.01 ATA each, five days a week for 2 months.
Study: NCT03918694

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Daily use of Vit C tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily use of placebo tablets
Study: NCT01512706

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 160Eu/0.5ml in infants (6-11 months old)
Description: inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 320Eu/0.5ml in infants (6-11 months old)
Description: inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 640Eu/0.5ml in infants (6-11 months old)
Description: inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 6-11 months old on day 0, 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1280Eu/0.5ml (without adjuvant) in infants (6-11 months old)
Description: inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 6-11 months old on day 0, 28

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0Eu/0.5ml in infants (6-11 months old)
Description: 0Eu/0.5ml placebo in 80 infants aged 6-11 months old on day 0, 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 160Eu/0.5ml in infants (12-23 months old)
Description: inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 320Eu/0.5ml in infants (12-23 months old)
Description: inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 640Eu/0.5ml in infants (12-23 months old)
Description: inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 12-23 months old on day 0, 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1280Eu/0.5ml (without adjuvant) in infants (12-23 months old)
Description: inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 12-23 months old on day 0, 28

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0Eu/0.5ml in infants (12-23 months old)
Description: 0Eu/0.5ml placebo in 50 infants aged 12-23 months old on day 0, 28
Study: NCT02133820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12 hourly capsule strong painkiller with antagonist fasted)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg 12 hourly capsule strong painkiller with antagonist fed
Study: NCT03443661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: oxaliplatin 85 mg/m2 irinotecan 150 mg/m2, 5FU 2,400 mg/m2 by 46 h infusion repeated at 2week intervals
Study: NCT04140331

Intervention type: DEVICE
Intervention: Accelerometer
Description: Patient will wear the accelerometer for 7 consecutive days to measure the level of physical activity.

Intervention type: DEVICE
Intervention: Accelerometer
Description: Patient will wear the accelerometer for 7 consecutive days to measure the level of physical activity.
Study: NCT02548806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine MBT 50µg
Description: Clonidine MBT 50µg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine MBT 100µg
Description: Clonidine MBT 100µg, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Catapres 100μg
Description: Catapres tablet 100μg, single dose
Study: NCT02851667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resident training programs
Description: A total of 24 resident training programs such as talks, day camp and thematic activities were delivered in the intervention estate by CFSC from June to November 2011. Each program included an introduction to the concepts of Learning Family and family 3Hs as well as how to promote family 3Hs through learning and communicating with family, delivered by interactive games and workshops.
Study: NCT06229301

Intervention type: PROCEDURE
Intervention: AI-predicted Nomogram

Intervention type: PROCEDURE
Intervention: AI-predicted Nomogram
Study: NCT00639860

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OSSIX-Plus
Description: resorbable collagen membrane
Study: NCT04290572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin capsules
Description: Jelly capsules of isotretinoin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin capsules
Description: Jelly capsules of isotretinoin
Study: NCT02548910

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Description: A central venous catheter will be inserted for every patient to measure central venous pressure, as is the standard of care in elective liver surgery. Strict aseptic technique will be maintained. A total volume of whole blood of 7-10 mL per kg of body weight will be removed, as tolerated. The volume of removed blood will not be replaced by intravenous fluid administration. Collected blood will be transfused back at the end of the liver parenchymal transection, or within 8 hours of collection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Citrated whole blood collection bag
Description: Transfusion Medicine will send the requested number of whole blood collection bags labelled with the patient's name and MRN. These whole blood collection bags are used in standard practice for collection of whole blood.
Study: NCT02134301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oritavancin
Study: NCT04513769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vegan diet
Description: Participants will receive a behavioral intervention on a vegan diet in partnership with a local vegan soul food restaurant
Study: NCT01901484

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Praziquantel
Description: All the registered S. mansoni infected children aged 1-5 years will be randomly divided into two treatment arms: single and double dose. A second those will be administered after two weeks following the last treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Praziquantel
Description: All the registered S. mansoni infected children aged 1-5 years will be randomly divided into two treatment arms: single and double dose. A second those will be administered after two weeks following the last treatment.
Study: NCT01650948

Intervention type: DEVICE
Intervention: RetnaGene AMD LDT

Intervention type: DEVICE
Intervention: RetnaGene AMD LDT
Study: NCT02727816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: filcon IV I (BC 8.6)
Description: control lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: filcon IV I (BC 8.7)
Description: control lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ocufilcon D
Description: test lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ocufilcon D
Description: test lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ocufilcon D
Description: test lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: methafilcon A (BC 8.6)
Description: control lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: methafilcon A (BC 8.7)
Description: control lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: somofilcon A
Description: test lens
Study: NCT02832102

Intervention type: PROCEDURE
Intervention: Standard treatment of SCCHN patients
Description: The interventions may include surgery, radiotherapy, chemotherapy or combined therapies, as recommended by best practice and international guidelines.

Intervention type: PROCEDURE
Intervention: Standard treatment of SCCHN patients
Description: The interventions may include surgery, radiotherapy, chemotherapy or combined therapies, as recommended by best practice and international guidelines.
Study: NCT03069833

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis
Description: computer-aided diagnosis to assist colonoscopists
Study: NCT02826408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole sodium
Description: WIll study effect of the medication on palpittions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pacebo
Description: Placebo comparison to active treatment
Study: NCT03857932

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Participants receive SLNB as well as non SLNs resection
Description: Participants only receive SLNB preoperative CT lymphography SLNB with stained non-SLN resection SLNB with ARM dissection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Participants receive SLNB as well as non SLNs resection
Description: Participants only receive SLNB preoperative CT lymphography SLNB with stained non-SLN resection SLNB with ARM dissection
Study: NCT00923351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumor Purged/CD25 Depleted Lymphocytes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine
Description: Tumor lysate/KLH pulsed dendritic cells (minimum of 1 X 10e6 cells/kg) on Day2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIL-7
Description: rhIL-7 (20 mcg/kg/dose SQ) approx. 48 hours prior to vaccine) Day 0, Day 14, Day 28 and Day 42

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine
Description: Tumor lysate/KLH Pulsed dendritic cell vaccine (1-5 X 10e7 cells/injection site, given in 3 sites intradermal) on Day 2, Day 16, Day 30, Day 44, Day 56, Day 70.
Study: NCT00532311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and stable statin therapy
Description: Lapaquistat acetate 50 mg, tablets, orally, once daily and stable statin therapy for up to 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stable statin therapy
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and stable statin therapy for up to 12 weeks.
Study: NCT03619577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequential training
Description: For cognitive training, the BrainHQ program, self-made teaching aids and board games will be used to train different cognitive functions of the participants. For physical exercise, we design the programs that involve balance or strength training components in the aerobic exercises. All participants will first perform 60 minutes of physical exercise followed by 60 minutes of cognitive training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequential training
Description: For cognitive training, the BrainHQ program, self-made teaching aids and board games will be used to train different cognitive functions of the participants. For physical exercise, we design the programs that involve balance or strength training components in the aerobic exercises. All participants will first perform 60 minutes of physical exercise followed by 60 minutes of cognitive training.
Study: NCT03146663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUC-1031 500 mg
Description: NUC-1031 500 mg/m2 on Days 1, 8, and 15 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUC-1031 750mg
Description: NUC-1031 750 mg/m2 on Days 1, 8, and 15 of a 28-day cycle
Study: NCT00500461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705
Description: GSK233705 will be available as IV infusion and oral solution containing Cellobiose octaacetate.
Study: NCT02748876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: His-Ventricular (HV) optimisation
Description: Optimisation of atrioventricular pacing interval
Study: NCT03385564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064
Description: subcutaneous injection
Study: NCT01899638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC/VI 125/25 mcg
Description: Combination in high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC/VI 62.5/25 mcg
Description: Combination in low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC 125 mcg
Description: LAMA mono in high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC 62.5 mcg
Description: LAMA mono in low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI 25 mcg
Description: LABA mono
Study: NCT03137953

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical Evaluation
Description: The skin pinch test would be done by three independent oncologists to assess ability for skin conservation. The decision for skin conservation would be taken by the surgeon intra-operatively based on clinical and radiological assessments.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Radiological Imaging
Description: Computed Tomography or Magnetic Resonance Imaging would be done by a radiologist and used to measure the distance between tumor and skin which would guide the decision for skin presevation. The decision for skin conservation would be taken by the surgeon intra-operatively based on clinical and radiological assessments.
Study: NCT03061292

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pectoral Nerve Block

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Without Pectoral Nerve Block
Study: NCT01607125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (Lu AA21004)
Description: encapsulated 20 mg tablets, orally, once daily for 13 to 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules, orally, once daily for 13 to 14 days
Study: NCT01633840

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Elemental E028 with added food allergens
Description: Test materials containing liquid vehicle (Elemental E028)with added food allergens (active)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Elemental E028
Description: Elemental E028 with no added food allergens
Study: NCT04704713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02288299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non invasive mechanical ventilation
Description: instrumental increase of inspiratory capacity and cough
Study: NCT00976157

Intervention type: PROCEDURE
Intervention: Bronchoscopy BAL
Description: The bronchoscope was passed through endotracheal tube via a specific adaptor without topical anesthesia. The bronchoscope was introduced and wedged into the segmental bronchial orifice where pneumonia was suspected. Five aliquots of 20ml sterile saline were instilled and aspirated gently. The first aliquot was discarded and the last 4 aliquots were pooled for analysis. Part of the retrieved specimen in the first BAL fluid was sent to the laboratory immediately after collection for measurement of sTREM-1 level, the rest of sample was sent to microbiology lab for quantitative culture.
Study: NCT04345692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: oral tablet administered by hospital staff or if discharged before day 5 - self administered oral tablet
Study: NCT02962245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: berberine
Study: NCT03385564

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection
Study: NCT02962245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: regular treatment
Description: such as 5-ASA,immunomodulating/suppressive agents or Anti-TNF therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: regular treatment
Description: such as 5-ASA,immunomodulating/suppressive agents or Anti-TNF therapy
Study: NCT01221818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6007
Description: E6007 50mg single dose or matching placebo
Study: NCT01433042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: capsule endoscopy
Description: capsule endoscopy procedure
Study: NCT04290572

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin capsules
Description: Jelly capsules of isotretinoin
Study: NCT03456700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auranofin
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO